摘要
Gene therapy is a potentially powerful tool used in cancer therapy. The strength of immune responses in- duced by some strategies is usually low, therefore, the development of agents capable of enhancing these responses is highlighted. The authors investigated the potential of an approach based on the hemagglutinin-neuraminidase（HN） of Newcastle disease virus（NDV） as a potential immune adjuvant. It was found that recombinant adenovirus（Ad） in- fected SGC7901 cells expressing HN exhibited both hemagglutinin（HA） and neuraminidase（NA） activities. It was demonstrated that administration of HN induced higher levels of the effector cytokines TNF-a, IFN-a and IFN-y and increased natural killer（NK） cell activity. Based on the therapeutic tumor model, the results show that the administra- tion of HN with Apoptin led to improved survival and tumor suppression. In conclusion, this study indicates that HN stimulates innate immune responses to make the activity of NK cells increased, which highlights the potential adju- vant activity of HN in cancer gene therapy.
Gene therapy is a potentially powerful tool used in cancer therapy. The strength of immune responses in- duced by some strategies is usually low, therefore, the development of agents capable of enhancing these responses is highlighted. The authors investigated the potential of an approach based on the hemagglutinin-neuraminidase（HN） of Newcastle disease virus（NDV） as a potential immune adjuvant. It was found that recombinant adenovirus（Ad） in- fected SGC7901 cells expressing HN exhibited both hemagglutinin（HA） and neuraminidase（NA） activities. It was demonstrated that administration of HN induced higher levels of the effector cytokines TNF-a, IFN-a and IFN-y and increased natural killer（NK） cell activity. Based on the therapeutic tumor model, the results show that the administra- tion of HN with Apoptin led to improved survival and tumor suppression. In conclusion, this study indicates that HN stimulates innate immune responses to make the activity of NK cells increased, which highlights the potential adju- vant activity of HN in cancer gene therapy.
基金
Supported by the National Science and Technology Major Projects for Major New Drugs Innovation and Development of China（No.2010ZX09401-305-14）, the National Natural Science Foundation of China（Nos.81072210, 81101140） and the Key Technologies R＆D Program of Jilin Province of China（Nos. 10ZDGG007, 201015166, 201101066）.
